North America’s medical devices industry saw a rise of 5.43% in deal activity during April 2021, when compared with the last 12-month average, led by $5bn acquisition of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 97 medical devices industry deals worth $9.6bn were announced for the region in April 2021, against the 12-month average of 92 deals.
Of all the deal types, venture financing saw most activity in April 2021 with 60 transactions, representing a 61.9% share for the region.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 25 deals, followed by private equity deals with 12 transactions, respectively capturing a 25.8% and 12.4% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $7.41bn, while venture financing and private equity deals totalled $1.43bn and $727.8m, respectively.
North America medical devices industry deals in April 2021: Top deals
The top five medical devices deals accounted for 79.7% of the overall value during April 2021.
The combined value of the top five medical devices deals stood at $7.62bn, against the overall value of $9.6bn recorded for the month.
The top five medical devices industry deals of April 2021 tracked by GlobalData were:
1) The $5bn merger of CA Healthcare Acquisition and LumiraDx
2) The $1.8bn acquisition deal with Luminex by DiaSorin
3) The Carlyle Group’s $435m private equity deal with Unchained Labs
4) The $200m acquisition of Genosity by InVitae
5) Mountain Crest AcquisitionII’s acquisition of Better Therapeutics for $187m.
